Evidence map›Paper›PMID 40647393›Full record

ArticleCancers2025

Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence After Prostatectomy: STARR (NCT05455736): An Early Analysis from the STARR Trial.

Niccolo' Bertini, Giulio Francolini, Vanessa Di Cataldo, Pietro Garlatti, Michele Aquilano, Giulio Frosini, Olga Ruggieri, Laura Masi, Raffaela Doro, Mauro Loi and 8 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05455736 (STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence After prostatectomy-a Prospective Observational Study -STARR), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05455736 unknown statusnot on this map

STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence After prostatectomy-a Prospective Observational Study -STARR

TypeobservationalSponsorAzienda Ospedaliero-Universitaria CareggiRan2021 to 2024Enrolled90ConditionsProstate Cancer, RelapseArmsStereotactic salvage radiotherapy for macroscopic prostate bed relapse
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Niccolo' BertiniDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.ORCID 0009-0006-1053-6265
Giulio FrancoliniRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, 50134 Florence, Italy.ORCID 0000-0002-1784-7203
Vanessa Di CataldoRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, 50134 Florence, Italy.
Pietro GarlattiRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, 50134 Florence, Italy.
Michele AquilanoCyberKnife Center, Istituto Fiorentino di Cura ed Assistenza, 50139 Florence, Italy.ORCID 0000-0001-9460-6406
Giulio FrosiniDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.
Olga RuggieriDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.
Laura MasiCyberKnife Center, Istituto Fiorentino di Cura ed Assistenza, 50139 Florence, Italy.
Raffaela DoroCyberKnife Center, Istituto Fiorentino di Cura ed Assistenza, 50139 Florence, Italy.
Mauro LoiRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, 50134 Florence, Italy.
Pierluigi BonomoRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-8999-5208
Daniela GretoRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, 50134 Florence, Italy.ORCID 0000-0002-2667-0841
Isacco DesideriDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.ORCID 0000-0002-9880-8387
Gabriele SimontacchiRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, 50134 Florence, Italy.ORCID 0000-0002-4005-6637
Icro MeattiniDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.ORCID 0000-0002-1861-2895
Riccardo CampiUnit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, 50134 Florence, Italy.ORCID 0000-0001-5237-0888
Lorenzo MasieriDepartment of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, 50134 Florence, Italy.
Lorenzo LiviDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PURPOSE/

objectivesSalvage radiotherapy (SRT) after a radical prostatectomy is a curative approach for patients with biochemical recurrence (BR). However, outcomes are often less favorable when imaging reveals macroscopic local recurrence. In such cases, dose escalation through stereotactic salvage radiotherapy (SSRT) may offer improved disease control. The STARR trial (NCT05455736) is a prospective, multicenter study evaluating the efficacy and safety of SSRT in patients with macroscopic prostate bed recurrence. This interim analysis reports early findings from the initial patient cohort. MATERIALS AND

methodsPatients with BR (PSA > 0.2 ng/mL) post-prostatectomy and PET-confirmed macroscopic recurrence (PSMA or Choline PET, confirmed by MRI) were eligible. Treatment involved CyberKnife

resultsAs of analysis, 51 patients were enrolled, with a median follow-up of 16 months (95% CI: 16-22). CBR and BR were achieved in 45.1% and 80.4% of patients, respectively. Events affecting bPFS, rPFS, and aPFS occurred in 12, 5, and 6 patients, with median values not yet reached. Toxicity was minimal, with two cases each of acute grade 2 GI and GU events, and one late grade 2 GI event. No grade ≥ 3 toxicities were reported.

conclusionEarly data support SSRT as a safe and a promising option for macroscopic local recurrence, with encouraging response rates and minimal toxicity.

Indexed as

adjuvant therapyprostate cancerradical prostatectomy

Identifiers

PMID40647393
PMCPMC12248716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.